161 related articles for article (PubMed ID: 33782292)
21. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
22. 18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient.
Marafi F; Sasikumar A; Aldaas M; Esmail A
Clin Nucl Med; 2021 Jan; 46(1):e65-e67. PubMed ID: 33181733
[TBL] [Abstract][Full Text] [Related]
23. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
Acar E; Kaya GÇ
Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
[TBL] [Abstract][Full Text] [Related]
24. 68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients.
Zang S; Shao G; Cui C; Li TN; Huang Y; Yao X; Fan Q; Chen Z; Du J; Jia R; Sun H; Hua Z; Tang J; Wang F
Oncotarget; 2017 Feb; 8(7):12247-12258. PubMed ID: 28103574
[TBL] [Abstract][Full Text] [Related]
25. Recurrent Brain Metastasis of Triple Negative Breast Cancer With High Uptake in 68Ga-PSMA-11 PET/CT.
Arslan E; Ergül N; Karagöz Y; Gedik AA; Çermik TF
Clin Nucl Med; 2021 Feb; 46(2):e106-e108. PubMed ID: 33065618
[TBL] [Abstract][Full Text] [Related]
26. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817
[TBL] [Abstract][Full Text] [Related]
27. Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
Sadeq A; Usmani S; Esmail AA; Fathallah W; Alfeeli MA; Marafi F
Clin Nucl Med; 2022 Jul; 47(7):627-628. PubMed ID: 35675136
[TBL] [Abstract][Full Text] [Related]
28. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma.
Demirci E; Ocak M; Kabasakal L; Decristoforo C; Talat Z; Halaç M; Kanmaz B
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1461-2. PubMed ID: 24756358
[No Abstract] [Full Text] [Related]
29.
Qi Z; Yao X; Su M; Huang R
Hell J Nucl Med; 2023; 26(2):155-156. PubMed ID: 37527052
[TBL] [Abstract][Full Text] [Related]
30. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B
Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic potential of PET/CT using a
Sawicki LM; Buchbender C; Boos J; Giessing M; Ermert J; Antke C; Antoch G; Hautzel H
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):102-107. PubMed ID: 26996777
[TBL] [Abstract][Full Text] [Related]
32. Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.
Pathmanathan S; Tariq A; Pearce A; Rhee H; Kyle S; Raveenthiran S; Wong D; McBean R; Marsh P; Goodman S; Dhiantravan N; Esler R; Dunglison N; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Goh JC; Gan CL; Roberts MJ
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):295-303. PubMed ID: 37592084
[TBL] [Abstract][Full Text] [Related]
33. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
[TBL] [Abstract][Full Text] [Related]
34. 68Ga-PSMA Uptake in Brain Metastasis of Gastric Carcinoma.
Kesim S; Oksuzoglu K
Clin Nucl Med; 2022 Sep; 47(9):e585-e586. PubMed ID: 35930713
[TBL] [Abstract][Full Text] [Related]
35. Small Cell Transformation of Metastatic Prostate Adenocarcinoma Diagnosed by Dual-Tracer PET/CT (
Parghane R; Basu S
J Nucl Med Technol; 2019 Mar; 47(1):85-87. PubMed ID: 30139889
[TBL] [Abstract][Full Text] [Related]
36. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
[TBL] [Abstract][Full Text] [Related]
37. Solitary Femoral Nodal Metastasis Identified With 68Ga-Prostate-Specific Membrane Antigen PET/CT.
Hilliar L; Yip JWL; Wong VCK; Le K; Mansberg R
Clin Nucl Med; 2021 Feb; 46(2):173-174. PubMed ID: 33315675
[TBL] [Abstract][Full Text] [Related]
38. 68Ga-Prostate-Specific Membrane Antigen-11-Avid Cardiac Metastases in a Patient With Adenoid Cystic Carcinoma, A Rare Presentation of a Rare Cancer.
Uijen MJM; van Boxtel W; van Herpen CML; Gotthardt M; Nagarajah J
Clin Nucl Med; 2020 Sep; 45(9):716-718. PubMed ID: 32701807
[TBL] [Abstract][Full Text] [Related]
39. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
40. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Verma P; Malhotra G; Agrawal R; Sonavane S; Meshram V; Asopa RV
Clin Nucl Med; 2018 Aug; 43(8):e265-e268. PubMed ID: 29894335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
